Trials / Terminated
TerminatedNCT04699461
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- ADC Therapeutics S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Loncastuximab Tesirine | IV infusion |
| DRUG | Idelalisib | Oral tablet |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2022-11-25
- Completion
- 2022-11-25
- First posted
- 2021-01-07
- Last updated
- 2023-10-23
- Results posted
- 2023-10-23
Locations
34 sites across 10 countries: United States, Belgium, France, Hungary, Israel, Italy, Poland, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04699461. Inclusion in this directory is not an endorsement.